New hope for lung scarring: TDI01 drug trial begins
NCT ID NCT07464912
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called TDI01 for people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. About 508 adults in China will receive either TDI01 or a placebo to see if the drug helps slow lung function decline over 24 to 52 weeks. The goal is to improve breathing and delay worsening of the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China-Japan Friendship Hospital
RECRUITINGBeijing, Beijing Municipality, 100023, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new daily pill slow lung scarring in IPF?
- Which finger or earlobe? a study tests the best spot for oxygen monitoring in lung disease
- Can a new drug slow lung scarring in IPF?
- Blood tests could unlock early clues for three major lung diseases
- AI could uncover hidden lung disease in routine chest X-Rays
- Inhaled drug could offer new hope for lung scarring disease